Author details

Full Name

Usman Baber

Affiliation

ORCID

Career Start Year

1999

Papers

353

H Index

Expertise

CM4AI Collaborator

PMID	Paper Title	Journal Title	Published Year
37517124	Impact of Frailty on Outcomes in Patients Who Underwent Transcatheter Mitral Valve Replacement.		2023
37742213	Predictive value of the thrombotic risk criteria proposed in the 2023 ESC guidelines for the management of ACS: insights from a large PCI registry.		2023
37587580	Bleeding and Ischemic Risks of TicagrelorÂ Monotherapy After CoronaryÂ Interventions.	J Am Coll Cardiol	2023
37806185	Clinically Driven Revascularization in High-Risk Patients Treated With Ticagrelor Monotherapy After PCI: Insights from the Randomized TWILIGHT Trial.	Am J Cardiol	2023
37634754	Practical solutions for implementation of blood cholesterol guidelines in clinical practice.		2023
37564132	Novel usage of everolimus-eluting coronary stent for intracranial atherosclerotic disease: a technical report and case series.		2023
37879803	Dyspnea-Related Ticagrelor Discontinuation After PercutaneousÂ Coronary Intervention.	JACC Cardiovasc Interv	2023
37870970	Safety and Efficacy of Ticagrelor Monotherapy in Patients With Acute Coronary Syndromes Undergoing Percutaneous Coronary Intervention: an Individual Patient Data Meta-analysis of TWILIGHT and TICO Randomized Trials.		2023
37094668	Fatal, ischemic and bleeding risk of patients meeting the selection criteria of the TWILIGHT trial: Insights from a large PCI registry.		2023
36649694	Ticagrelor with or without aspirin in high-risk patients with anaemia undergoing percutaneous coronary intervention: a subgroup analysis of the TWILIGHT trial.	Eur Heart J Cardiovasc Pharmacother	2023
37335828	Defining Strategies of Modulation of Antiplatelet Therapy in Patients With Coronary Artery Disease: A Consensus Document from the Academic Research Consortium.	Circulation	2023
37080466	Biolimus-eluting vs. other limus-eluting stents in NSTE-ACS: A pooled analysis of GLASSY and TWILIGHT.	Int J Cardiol	2023
37459570	Thrombotic risk in patients with acute coronary syndromes discharged on prasugrel or clopidogrel: results from the PROMETHEUS study.	Eur Heart J Acute Cardiovasc Care	2023
36493579	New Criteria to Identify Patients at Higher Risk for Cardiovascular Complications After Percutaneous Coronary Intervention.		2023
36754514	P2Y Inhibitor Monotherapy or Dual Antiplatelet Therapy After Complex Percutaneous Coronary Interventions.		2023
36564015	Efficacy and safety of P2Y12 inhibitor monotherapy after complex PCI: a collaborative systematic review and meta-analysis.		2023
37380247	Timing and Predictors of Myocardial Infarction or Stent Thrombosis in High-Bleeding Risk Patients Undergoing PCI.		2023
37187289	Prognostic value of high-sensitivity C-reactive protein among chronic kidney disease patients undergoing percutaneous coronary intervention.		2023
36691863	Impact of complex percutaneous coronary intervention features on clinical outcomes in patients with or without chronic kidney disease.		2023
36792250	Educational Experience of InterventionalÂ Cardiology Fellows in the United StatesÂ and Canada.	JACC Cardiovasc Interv	2023
37295179	Impact of Obesity on Outcomes in Patients Undergoing Transcatheter Mitral Valve Repair With MitraClip.		2023
37037088	Impact of Frailty on In-Hospital Outcomes in Patients Who Underwent Percutaneous Left Atrial Appendage Occlusion.		2023
36599586	Switching Between Intravenous and Oral P2Y Inhibition: Easier Said Than Done.		2023
31270529	Efficacy and safety of alirocumab and evolocumab: a systematic review and meta-analysis of randomized controlled trials.	European Heart Journal	2022
35656720	Antithrombotic strategy variability in atrial fibrillation and obstructive coronary disease revascularised with percutaneous coronary intervention: primary results from the AVIATOR 2 international registry.	EuroIntervention	2022
35461697	Impact of Small Valve Size on 1-Year Outcomes After Transcatheter Aortic Valve Implantation in Women (from the WIN-TAVI Registry).	American Journal of Cardiology	2022
35389474	Perioperative management of P2Y12 inhibitors in patients undergoing cardiac surgery within 1 year of PCI.	Eur Heart J Cardiovasc Pharmacother	2022
35697777	P2Y<sub>12</sub> inhibitor monotherapy in patients undergoing percutaneous coronary intervention.	Nat Rev Cardiol	2022
35680196	Polymer-Based Versus Polymer-Free Stents in High Bleeding Risk Patients: Less Is Not Always More.	JACC: Cardiovascular Interventions	2022
36202563	Bleeding and Ischemic Outcomes With Ticagrelor Monotherapy According to Body Mass Index.	JACC Cardiovasc Interv	2022
35981822	Medication Nonadherence: A Challenging Conundrum for Clinical Trials, Patients, and Clinicians.	Journal of the American College of Cardiology	2022
35979636	Ticagrelor with and without aspirin in patients with a prior coronary artery bypass graft undergoing percutaneous coronary intervention: the TWILIGHT-CABG study.	EuroIntervention	2022
34347202	Performance of the academic research consortium high-bleeding risk criteria in patients undergoing PCI for acute myocardial infarction.	Journal of Thrombosis and Thrombolysis	2022
35317615	Ticagrelor With or Without Aspirin in Chinese Patients Undergoing Percutaneous Coronary Intervention: A TWILIGHT China Substudy.	Circ Cardiovasc Interv	2022
34988782	Relationship between hemoglobin A1C and characteristics of plaque vulnerability in stable coronary disease: an optical coherence tomography study.		2022
34459481	Guided and unguided de-escalation from potent P2Y12 inhibitors among patients with acute coronary syndrome: a meta-analysis.	European Heart Journal - Cardiovascular Pharmacotherapy	2022
35033468	Ticagrelor Monotherapy After PCI in High-Risk Patients With Prior MI: A Prespecified TWILIGHT Substudy.	JACC Cardiovasc Interv	2022
34973905	Coronary Artery Calcification and Mortality After Revascularization: Look Beyond the Heart.	JACC: Cardiovascular Interventions	2022
34386899	Perioperative risk and antiplatelet management in patients undergoing non-cardiac surgery within 1 year of PCI.	J Thromb Thrombolysis	2022
35151783	Prognostic Value of Baseline Inflammation in Diabetic and Nondiabetic Patients Undergoing Percutaneous Coronary Intervention.	Canadian Journal of Cardiology	2022
34656457	The 5W1H in antiplatelet monotherapy after percutaneous coronary intervention: what, who, where, when, why, and how?	Revista espanola de cardiologia (English ed.)	2022
34881696	Safety and efficacy of ticagrelor monotherapy according to drug-eluting stent type: the TWILIGHT-STENT study.	EuroIntervention	2022
35058052	Effect of Elevated C-Reactive Protein on Outcomes After Complex Percutaneous Coronary Intervention for Angina Pectoris.	American Journal of Cardiology	2022
35178746	Assessment and validation of a novel fast fully automated artificial intelligence left ventricular ejection fraction quantification software.	Echocardiography	2022
35325085	Ticagrelor monotherapy after PCI in patients with concomitant diabetes mellitus and chronic kidney disease: TWILIGHT DM-CKD.	Eur Heart J Cardiovasc Pharmacother	2022
34474588	Sex-Related Differences in the Prevalence and Prognostic Value of the Academic Research Consortium for High Bleeding Risk Criteria.	Circulation: Cardiovascular Interventions	2021
36712391	Mobile application to optimize care for ST-segment elevation myocardial infarction patients in a large healthcare system, STEMIcathAID: rationale and design.		2021
32198837	Sex differences in 1-year clinical outcomes after percutaneous coronary intervention with COMBO stents: From the COMBO collaboration.	Catheterization and Cardiovascular Interventions	2021
32406998	Safety and efficacy of the bioabsorbable polymer everolimus-eluting stent versus durable polymer drug-eluting stents in high-risk patients undergoing PCI: TWILIGHT-SYNERGY.	Catheterization and Cardiovascular Interventions	2021
32333721	Outcomes of Impella-supported high-risk nonemergent percutaneous coronary intervention in a large single-center registry.	Catheterization and Cardiovascular Interventions	2021